Short answer
Enliven Therapeutics, Inc. (ELVN) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$32M
- −28.2% YoY · −37.5% QoQ
- EPS (diluted)
- −$0.49
- −2.1% YoY · −28.9% QoQ
Source: XBRL data from the Enliven Therapeutics, Inc. (ELVN) Q2 2026 10-Q on SEC EDGAR. USD.
Enliven Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product or other revenue generated
- Net loss $32.5M vs $25.3M YoY; operating margin not applicable with zero revenue
- ELVN-001 R&D $8.3M vs $6.0M; ELVN-002 R&D $1.2M vs $3.5M
- Cash, equivalents and marketable securities $895.2M as of June 30, 2026
- $460.0M gross proceeds from June 2026 public offering; funding sufficient for at least 12 months
Risk Factors
- ELVN-002 development discontinued while exploring strategic alternatives, concentrating resources on ELVN-001 and its upcoming pivotal trial
- Clinical-stage regulatory risk: FDA may require bridging studies for alternative ELVN-001 tablet formulations
- ELVN-001 Phase 1 outcomes may fail to support later-stage efficacy or safety requirements
- June 2026 ENABLE data were positive, but no clinical trial has yet been completed
- Net loss $56.1 million and accumulated deficit $403.3 million as of June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Enliven Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.